Literature DB >> 3495235

Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro.

J P Sommadossi, R Carlisle.   

Abstract

The effects of 3'-azido-3'-deoxythymidine (AZT) and 9-(1,3-dihydroxy-2-propoxymethyl)guanine on myeloid and erythroid colony-forming cells were studied by clonogenic assays. Both consistently inhibited granulocyte-macrophage CFU (CFU-GM) and erythroid burst-forming units in a dose-dependent fashion. Concentrations of AZT and 9-(1,3-dihydroxy-2-propoxymethyl)guanine required for 50% inhibition of CFU-GM were, respectively, 0.9 +/- 0.1 and 2.7 +/- 0.5 microM; those required for 90% inhibition were, respectively, 34.0 +/- 2.8 and 35.7 +/- 3.6 microM. Erythroid burst-forming units were less sensitive to high concentrations of AZT than were CFU-GM.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3495235      PMCID： PMC174750          DOI： 10.1128/AAC.31.3.452

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A.

Authors:  N N Iscove; F Sieber; K H Winterhalter
Journal:  J Cell Physiol       Date:  1974-04       Impact factor: 6.384

2.  Growth of mouse megakaryocyte colonies in vitro.

Authors:  D Metcalf; H R MacDonald; N Odartchenko; B Sordat
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

3.  In vitro erythropoiesis. II. Cytochemical enumeration of erythroid stem cells (CFU-e and BFU-e) from normal mouse and human hematopoietic tissues.

Authors:  V S Gallicchio; M J Murphy
Journal:  Exp Hematol       Date:  1979-05       Impact factor: 3.084

4.  Stimulatory activity for human pluripotent hemopoietic progenitors produced by a human T-lymphocyte cell line.

Authors:  A A Fauser; H A Messner; A J Lusis; D W Golde
Journal:  Stem Cells       Date:  1981       Impact factor: 6.277

5.  Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro.

Authors:  R W McGuffin; F M Shiota; J D Meyers
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

6.  Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.

Authors:  R Yarchoan; R W Klecker; K J Weinhold; P D Markham; H K Lyerly; D T Durack; E Gelmann; S N Lehrman; R M Blum; D W Barry
Journal:  Lancet       Date:  1986-03-15       Impact factor: 79.321

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Neutrophil kinetics in chronic neutropenia.

Authors:  T H Price; M Y Lee; D C Dale; C A Finch
Journal:  Blood       Date:  1979-09       Impact factor: 22.113

9.  Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine.

Authors:  D F Smee; J C Martin; J P Verheyden; T R Matthews
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205
  10 in total
  53 in total

1.  A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation.

Authors:  Seung Tae Kim; Mark H Lee; Sung Yong Kim; Seok Jin Kim; Dong Hwan Kim; Jun Ho Jang; Kihyun Kim; Won Seog Kim; Chul Won Jung
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 2.  Clinical pharmacokinetics of zidovudine. An overview of current data.

Authors:  J M Collins; J D Unadkat
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

3.  Sensitivity of CFU-GM from normal human bone marrow and leukaemic clonogenic cells (CFU-L) from blood of patients with myelogenous leukaemia to 3'-deoxy-3'-fluorothymidine in comparison to 3'-azido-3'-deoxythymidine.

Authors:  I W Blau; E Elstner; M Waechter; R Ihle; M von Janta-Lipinski; P Langen
Journal:  Blut       Date:  1989-11

4.  Inhibition of immune functions by antiviral drugs.

Authors:  W Heagy; C Crumpacker; P A Lopez; R W Finberg
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

Review 5.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

6.  Evaluation of continuous cell lines in antiviral studies with murine cytomegalovirus.

Authors:  D F Smee; A Colletti; H A Alaghamandan; L B Allen
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

Review 7.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Modified antisense oligodeoxynucleotides against the splice acceptor site of tat do not inhibit in vitro hematopoietic colony growth in HIV-positive patients.

Authors:  R G Geissler; J Muth; A Maurer; U Mentzel; M Mag; J W Engels; D Hoelzer; A Ganser
Journal:  Ann Hematol       Date:  1995-08       Impact factor: 3.673

Review 9.  Zidovudine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  H D Langtry; D M Campoli-Richards
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

10.  Potent anti-murine cytomegalovirus activity and reduced nephrotoxicity of ganciclovir cyclic phosphonate.

Authors:  D F Smee; E J Reist
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.